B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
GALT
Galectin TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-25
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.4
Score
AI commentary
News tone is positive after the June FDA update, and secondary coverage reported an approximately 22% share-price surge, but the event appears partly priced in and the July 24 anchor price was $3.47. No social aggregate, options data, short-interest data, or analyst revision data is available in the packet; missing coverage is not positive evidence. The negative deterministic return prior and insider-sale overhang favor monitoring rather than chasing the regulatory move.
RankAlpha Sentiment Codex - 2026-07-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-23eventFDA Type C alignment de-risked the Phase 3 path [#SEC-8K-2026-06-23]Medium impact
Galectin reported agreement with FDA on a composite endpoint, centralized endoscopy review, a single 2 mg dose, and a traditional full-approval pathway. The event appears substantially reflected in the prior rally.
2026-08-31catalystPost-FDA event digestion and insider-sale overhang [#SEC-FORM4-2026-06-30]High impact
The June FDA update is no longer new. A director sold 22,268 shares and the chief medical officer sold 47,467 shares at $5.04 after option exercise; this is a sentiment overhang, not operating evidence.
2026-09-30catalystPlanned Phase 3 protocol submission [#SEC-8K-2026-06-23]High impact
The company plans to submit the final Phase 3 protocol in Q3 2026 for a registration study broadly comparable in size to NAVIGATE.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-25 • Updated nightlySource: Internal modelMethodology